Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Organon (OGN)
NYSE:OGN
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.93Last Year’s EPS
1.22Same Quarter Last Year
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 13, 2025
|% Change Since: 4.01%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Neutral
Organon demonstrated consistent revenue growth and strength in key segments like women's health and biosimilars. However, the company faces significant challenges, including the loss of exclusivity for Atozet, pricing pressures, and substantial one-time costs. The company is actively implementing cost-saving measures to mitigate these challenges.Company Guidance
During Organon's Fourth Quarter and Full Year 2024 Earnings Call, the company provided detailed guidance for the upcoming year. For 2025, Organon forecasts revenue between $6.125 billion and $6.325 billion, factoring in an anticipated $200 million foreign currency headwind and a $200 million revenue impact from the loss of exclusivity (LOE) of Atozet in Europe. They expect the adjusted EBITDA margin to range from 31% to 32%, maintaining a 31% floor excluding in-process research and development (IPR&D). Key growth drivers include Nexplanon, projected to exceed $1 billion in revenue, and Vtama, which together with Emgality, is expected to contribute significantly to Organon's revenue growth. The company's strategic focus on operational efficiencies aims to achieve $200 million in cost savings, enhancing profitability despite the LOE challenges.Consistent Revenue Growth
Organon achieved $6.4 billion in revenue for 2024, marking a 3% growth rate at constant currency, maintaining three consecutive years of growth across all franchises.
Strong Performance in Women's Health
The women's health franchise grew 5% ex-exchange, led by Nexplanon, which increased 17% ex-FX, achieving its best annual performance ever.
Biosimilars Franchise Growth
Biosimilars saw a 12% growth at constant currency, driven by capturing more than the contractual share of the Brazil tender for Ontruzant.
Successful Vtama Launch
Organon launched Vtama with strong NRX growth of 51% over a 13-week average and plans to launch in Canada later in 2025.
Cost Efficiency Measures
Organon implemented initiatives expected to drive $200 million in operating savings for 2025, focusing on restructuring and streamlining operations.
---
OGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
OGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 13, 2025 | $14.70 | $16.32 | +11.02% |
| Oct 31, 2024 | $17.62 | $18.45 | +4.71% |
| Aug 06, 2024 | $19.56 | $18.07 | -7.62% |
| May 02, 2024 | $18.00 | $18.64 | +3.56% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Organon (OGN) report earnings?
Organon (OGN) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Organon (OGN) earnings time?
Organon (OGN) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OGN EPS forecast?
OGN EPS forecast for the fiscal quarter 2025 (Q1) is 0.93.
---